Table 1.

Patient characteristics.

Dose level-1Dose level 1
(D-1)(D1)Overall
N31 (88.6)4 (11.4)35 (100%)
Age, y
 Mean/std64.9/10.263.6/7.564.7/9.9
 Median/min/max67.0/39.2/82.564.7/54.0/71.067.0/39.2/82.5
Gender
 Male29 (93.5%)3 (75.0%)32 (91.4%)
 Female2 (6.5%)1 (25.0%)3 (8.6%)
Race
 White31 (100.0%)3 (75.0%)34 (97.1%)
 Black, African1 (25.0%)1 (2.9%)
 American
ECOG
 014 (45.2%)1 (25.0%)15 (42.9%)
 115 (48.4%)3 (75.0%)18 (51.4%)
 22 (6.5%)2 (5.7%)
Site
 Esophagus25 (80.6%)4 (100.0%)29 (83%)
 Stomach6 (19.4%)6 (17%)
Histology
 Squamous cell2 (6.5%)1 (25.0%)3 (8.6%)
 Adenocarcinoma26 (83.9%)3 (75.0%)29 (82.9%)
 Poorly differentiated1 (3.2%)1 (2.9%)
 Adenosquamous2 (6.5%)2 (5.7%)
Clinical stage
 II1 (3.2%)1 (2.9%)
 III1 (3.2%)1 (2.9%)
 IV25 (80.6%)4 (100.0%)29 (82.9%)
 MISC4 (12.9%)4 (11.4%)
Completed cycles
 Mean/std error7.4/0.85.5/2.27.2/0.7
 Median/min/max8.0/1.0/17.04.0/2.0/12.06.0/1.0/17.0